Over the past two decades, there has been a significant increase in the number of adults in the United States with small fiber neuropathy (SFN), but in many cases, no cause can be determined. The ...

ST-503 will be evaluated in a phase 1/2 trial with the first patient scheduled to receive the therapy in the coming months. The Food and Drug Administration (FDA) has granted Fast Track designation to ...

Small fiber neuropathy (SFN) is a chronic and debilitating condition caused by damage to peripheral sensory nerves, which are responsible for pain, temperature sensation and autonomic functions.

Vixotrigine, a non-opioid investigational pain drug, has the potential to address significant unmet medical needs of individuals living with chronic painful neuropathy CAMBRIDGE, Mass., Sept. 16, 2021 ...

A: The brain sends/receives electric signals that control/sense different muscles and body functions/sensory signals. These electrical signals travel either directly from the brain to the signal ...

The number of people experiencing numbness, tingling and pain in their feet with no known cause has been increasing over the last two decades, according at a new study. Called small fiber neuropathy, ...

Prolonged, often disabling, small-fiber neuropathy in long COVID may be caused by a defective immune response, a small longitudinal study suggested. Peripheral neuropathy was identified in 59% of 17 ...

Please provide your email address to receive an email when new articles are posted on . The FDA has cleared an investigational new drug application for an epigenetic regulator to treat intractable ...

RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted ...

In 1982, at the age of 31, I was diagnosed with a small-fiber length-dependent sensory peripheral neuropathy. Despite extensive laboratory assessments (including genome sequencing), the cause is ...

The use of opioids not recommended in guidelines in Taiwan cancer patients. Enhancing evaluation of cancer cachexia (CC) and sarcopenia through skeletal muscle mass (SMM) determination in patients ...

(RTTNews) - Biogen Inc. (BIIB) announced positive results from its Phase 2 CONVEY study of vixotrigine or BIIB074, a non-opioid investigational oral pain drug being evaluated for the treatment of ...